Highlights China Medical System Holdings Limited

Equities

867 KYG211081248

Market Closed - Hong Kong S.E. Other stock markets 04:08:27 2024-07-12 am EDT			5-day change	1st Jan Change
6.61 ^HKD	+2.48%		-1.34%	-52.24%

Jun. 25	China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China	CI
Jun. 18	China Medical System Gets Drug Registration Certificate for Lesion Visualization Drug in China	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China	Jun. 25	CI
China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection	Jun. 18	CI
Final dividend	May. 12	FA
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023	May. 09	CI
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China	Apr. 23	CI
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
China Medical System Registers New Vitiligo Drug in Macau	Apr. 16	MT
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.	Apr. 02	CI
Incyte, China Medical System Sign Collaboration, License Agreement	Apr. 01	MT
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia	Apr. 01	CI
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024	Mar. 27	CI
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial	Mar. 19	MT
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China	Mar. 19	CI
China Medical System Obtains Nod For Trials of Two Drugs	Feb. 08	MT
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed	Feb. 07	CI
China Medical Gains License to Sell Kidney Disease Drug Across China	Feb. 05	MT
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China	Dec. 12	CI
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China	Dec. 04	CI
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million.	23-09-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights China Medical System Holdings Limited

Equities

867

KYG211081248

Highlights

Filters